“This is a pivotal step, and once the scientific article is published, it will be a valuable tool for the company in marketing and sales efforts. Additionally, the article will be an important basis in upcoming reimbursement processes," says Anders Weilandt, CEO of Chordate Medical.

Chordate Medical will announce when the authors have received approval for publication in the journal in question.

The final results from Chordate Medical's PM007 study demonstrate that the company's migraine treatment, K.O.S, exhibits a significant reduction in the number of headache days and migraine days in adult patients with moderate to severe chronic migraine. The results also show that K.O.S maintains a sustained therapeutic effect and is well-tolerated, with few unexpected side effects. This sets apart the unique treatment, which is non-pharmaceutical, from other preventative treatments in the market, also due to its favorable side effect profile.